Are multiple markers the future of prostate cancer diagnostics?

  • Mikolajczyk S
  • Song Y
  • Wong J
 et al. 
  • 19


    Mendeley users who have this article in their library.
  • 74


    Citations of this article.


Prostate specific antigen (PSA) is the most successful and widely employed cancer serum marker in use today. There is growing evidence that the introduction of wide PSA screening and earlier detection can result in decreased cancer mortality associated with a decline in metastatic disease. PSA circulates in a number of distinct forms. Measurement of these in addition to total PSA significantly increases diagnostic utility. Diagnostic utility is likely to be further increased by adding kallikreins, cytokines, growth factors, receptors and cellular adhesion factors to the biomarker panel. The need for multiple markers reflects the multidimensional nature of prostate disease which ranges from metastatic cancer to indolent cancer to benign hyperplasia and inflammation, all of which require distinct treatments and medical interventions. © 2004 The Canadian Society of Clinical Chemists. All rights reserved.

Author-supplied keywords

  • Markers
  • Prostate cancer
  • Prostate-specific antigen

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Stephen D. Mikolajczyk

  • Yong Song

  • James R. Wong

  • Robert S. Matson

  • Harry G. Rittenhouse

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free